Stock AnalizINSMED (INSM) earnings for the quarter ended September 2026: EPS misses estimates
INSMED reported results for the quarter ended September 2026 on October 29, 2026. Adjusted earnings per share came in at -$0.46 against the analysts’ average forecast of -$0.37, a miss of 23.7%.
Revenue for the quarter was $524 million, up 268.4% from $142 million in the same quarter a year earlier.
The market’s verdict: the stock rose 15.1% on the first trading day after the report.
The last four quarters
INSMED has beaten the analysts’ EPS forecast in 2 of the last 4 quarters.
| Quarter | EPS | Forecast | Surprise | Revenue growth | Price reaction |
|---|---|---|---|---|---|
| Sep 2026 | -$0.46 | -$0.37 | −23.7% | +268% | +15.1% |
| Jun 2026 | -$0.06 | -$0.68 | +91.2% | +296% | +32.4% |
| Mar 2026 | -$0.76 | -$1.00 | +23.9% | +230% | −26.1% |
| Sep 2025 | -$1.75 | -$1.37 | −27.8% | +52% | +13.6% |
What comes next
Analysts expect EPS of -$0.34 for the next quarter on average and -$1.67 for the fiscal year ending December 31, 2026.
The average analyst price target is $194.18, 60% above the current price of $121.16.
Valuation and score
INSMED scores 1.2 out of 5 overall on Stock Analiz (weak). Full INSMED analysis with 10 years of financials
Frequently asked questions
What was INSMED’s EPS for the quarter ended September 2026?
-$0.46 adjusted per share, against an analyst consensus of -$0.37.
How much revenue did INSMED report?
$524 million, up 268.4% year over year.
More
This report was written automatically from the published numbers within hours of the release. It is information, not investment advice.